Sanofi’s Lemtrada could be too expensive if approved for MS
This article was originally published in Scrip
Executive Summary
An editorial accompanying the publication of the pivotal, Phase III CARE-MS I and CARE-MS II studies investigating Genzyme's multiple sclerosis (MS) treatment, Lemtrada (alemtuzumab) has raised concerns over the drug's potential cost and its availability for patients who have started treatment and need another course.